Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Non-Current Assets (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Other Non-Current Assets for 13 consecutive years, with $392000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 17.82% to $392000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $392000.0 through Dec 2025, down 17.82% year-over-year, with the annual reading at $454000.0 for FY2025, 37.47% down from the prior year.
  • Other Non-Current Assets hit $392000.0 in Q4 2025 for Vistagen Therapeutics, down from $405000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $726000.0 in Q1 2024 to a low of $47800.0 in Q3 2021.
  • Historically, Other Non-Current Assets has averaged $278820.0 across 5 years, with a median of $217450.0 in 2021.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 85.14% in 2021 and later skyrocketed 618.81% in 2024.
  • Year by year, Other Non-Current Assets stood at $100900.0 in 2021, then changed by 0.0% to $100900.0 in 2022, then skyrocketed by 47.37% to $148700.0 in 2023, then skyrocketed by 220.78% to $477000.0 in 2024, then dropped by 17.82% to $392000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for VTGN at $392000.0 in Q4 2025, $405000.0 in Q3 2025, and $472000.0 in Q2 2025.